

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN INSTITUTIONAL LLC,  
Petitioner,

v.

NOVO NORDISK A/S,  
Patent Owner.

---

Case IPR2020-00324  
Patent 8,114,833

---

**PATENT OWNER'S UPDATED MANDATORY NOTICE INFORMATION  
UNDER 37 C.F.R. § 42.8**

IPR2020-00324

Patent 8,114,833 B2

Pursuant to 37 C.F.R. § 42.8(a)(3), Patent Owner, Novo Nordisk A/S

(“Novo Nordisk”), hereby files its first Updated Mandatory Notice:

**I. Related Matters (§ 42.8(b)(2))**

Patent Owner is aware of the following district court litigations involving U.S. Patent No. 8,114,833: *Novo Nordisk Inc. and Novo Nordisk A/S v. Mylan Institutional LLC*, No. 19-cv-1551-CFC (D. Del.); *Novo Nordisk Inc. and Novo Nordisk A/S v. Mylan Institutional LLC*, No. 19-cv-164 (N.D. W. Va.); *Novo Nordisk Inc. and Novo Nordisk A/S v. Sandoz Inc.*, No. 20-cv-747-CFC (D. Del.); *Novo Nordisk Inc. and Novo Nordisk A/S v. Sandoz Inc.*, 20-cv-6842-RMB-AMD (D.N.J.). Case Nos. 19-cv-1551-CFC, 20-cv-747-CFC, and 20-cv-6842-RMB-AMD are currently pending. Case No. 19-cv-164 has been voluntarily dismissed.

U.S. Patent Application No. 16/260,204, which is pending and was filed on January 29, 2019, and U.S. Patent Application No. 16/910,945, which is pending and was filed on June 24, 2020, both claim the benefit of U.S. Application No. 11/435,977, which is the application that issued as U.S. Patent No. 8,114,833.

**II. Counsel and Service Information (§§ 42.8(b)(3) and (4))**

Patent Owner will maintain its lead and backup counsel as shown below:

IPR2020-00324  
Patent 8,114,833 B2

Lead Counsel:  
Jeffrey J. Oelke, Reg. No. 37,409  
FENWICK & WEST LLP  
902 Broadway, Suite 14  
New York, NY 10010  
Tel: (212) 430-2600  
Fax: (650) 938-5200  
joelke@fenwick.com

Backup Counsel:  
Ryan P. Johnson  
Laura T. Moran  
FENWICK & WEST LLP  
902 Broadway, Suite 14  
New York, NY 10010  
(212) 430-2600 (tel)  
(650) 938-5200 (fax)  
ryan.johnson@fenwick.com  
laura.moran@fenwick.com

Please address all correspondence to the lead and backup counsel at the above addresses and to Novo833IPR@fenwick.com. Patent Owner consents to electronic service to the e-mail addresses above for lead and backup counsel and to Novo833IPR@fenwick.com.

Dated: June 29, 2020

Respectfully submitted,

/Jeffrey J. Oelke/  
Jeffrey J. Oelke (Reg. No. 37,409)  
FENWICK & WEST LLP  
902 Broadway, Suite 14  
New York, NY 10010  
(212) 430-2600 (tel)  
(650) 938-5200 (fax)  
joelke@fenwick.com

*Counsel for Novo Nordisk A/S*

## CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing Patent Owner's Updated Mandatory Notice Information Under 37 C.F.R. § 42.8 was served on June 29, 2020, by filing this document through the Patent Trial and Appeal Board End to End System, as well as delivering a copy via electronic mail upon the following attorneys of record for the Petitioner:

Brandon M. White  
Lara Dueppen  
Perkins Coie LLP  
white-ptab@perkinscoie.com  
dueppen-ptab@perkinscoie.com  
liraglutide@perkinscoie.com

Date: June 29, 2020

Respectfully submitted,

/ Jeffrey J. Oelke/  
Jeffrey J. Oelke (Reg. No. 37,409)

*Counsel for Novo Nordisk A/S*